Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The Significance of Prenuptial Arrangements in Separation Procedures - 2Ancient Pompeii construction site reveals the process for creating Roman concrete
- 3'Stranger Things' series finale trailer shows Hawkins gang gearing up for last battle with Vecna
- 4South Carolina confirms 124 new measles cases as outbreak on the Arizona-Utah line grows
- 5Australia Cracks Down on Gambling Ads as Prediction Markets Like Polymarket Remain Blocked
- Iranian rockets hit Tel Aviv area, injuring six
- Israel has clear objectives south of Litani River, but will face difficult choices further north
- The Response to Self-improvement: Embracing a Development Outlook
- ADHD drugs work, but not the way experts thought
- What's going around right now? COVID, flu, stomach bug on the rise
- How to watch 'Tell Me Lies' Season 3: Episode release times, streaming info and more
- These Cities Led Global Jet-Setting In 2025, According To New Data
- $30K Disability Scam Implodes After Surf Trip in Mexico
- Exclusive-Head of Pemex's production arm to step down in coming days, sources say
